Monsanto is dead. Now what?

The lightning rod for resentment won’t be there to kick around anymore

It seems Monsanto is finally out of its misery. Arguably the most detested company in the world, it will likely cease to exist with Bayer’s acquisition. Monsanto’s own attempt to acquire Swiss-based Syngenta not only failed, but also was received with extreme prejudice. But now with Bayer’s acquisition of the St. Louis-based company, Monsanto, or

University of Saskatchewan’s Richard Gray says there’s plenty of reason to be concerned about the Bayer-Monsanto merger.

Canola farmers worried about Bayer-Monsanto merger

The fear is the new company’s market power will result in higher seed prices and less innovation unless regulators order some divestiture of assets

Farmers who are worried about chemical and seed giants Bayer and Monsanto merging should be, according to one prominent agriculture economist. With 94 per cent of western Canadian canola containing Bayer’s Liberty Link or Monsanto’s Roundup Ready traits, the new company will have tremendous market power resulting in higher canola seed prices for farmers, said


(CropScience.Bayer.ca)

U.S. lawmakers skeptical of ag chemical, seed merger wave

Washington | Reuters — U.S. lawmakers expressed concern on Tuesday over a wave of mergers among companies that sell farmers their seeds, herbicides and insecticides, worrying that the deals could lead to higher prices and less innovation at a time of dropping farm incomes. Senator Richard Blumenthal, a Democrat from Connecticut, said the proposed mergers

(Dave Bedard photo)

U.S. EPA says glyphosate likely not carcinogenic

Chicago | Reuters — The U.S. Environmental Protection Agency on Friday said its current position on glyphosate, the key ingredient in Monsanto’s Roundup herbicide, is that the chemical is not likely carcinogenic to humans. The agency’s “proposed” position on the controversial chemical was outlined in a 227-page paper it published on the regulations.gov website, which



(Monsanto.com)

Climate’s field software en route to Eastern Canada

San Francisco-based ag software firm and Monsanto subsidiary The Climate Corporation is making a run for the border with its Climate FieldView farm data suite. Appearing Wednesday at Canada’s Outdoor Farm Show, company representatives announced their suite of digital farm data tools, Climate FieldView, will be offered for sale in Eastern Canada this winter, for


Bayer CEO Werner Baumann (l) and Monsanto CEO Hugh Grant on Wednesday announced plans for a friendly merger in which Bayer will buy all Monsanto stock for US$128 per share. (PRNewsFoto/Bayer)

Bayer clinches Monsanto with raised US$66 billion bid

New York/Frankfurt | Reuters — German drugs and crop chemicals company Bayer has won over U.S. seeds firm Monsanto with an improved takeover offer of US$66 billion including debt, ending months of wrangling after increasing its bid for a third time. The $128 a share deal announced on Wednesday, up from Bayer’s previous offer of

(Dave Bedard photo)

Bayer sweetens Monsanto bid as talks enter final stretch

Reuters — German pharmaceutical and crops manufacturer Bayer said on Monday that its negotiations with Monsanto had advanced, and that it was now willing to offer more than US$65 billion to acquire the world’s largest seeds company. Bayer’s announcement came as the gap in price expectations between the two companies has narrowed significantly, although important


(Syngenta.com)

U.S. watchdog clears ChemChina’s takeover of Syngenta

Zurich | Reuters — A U.S. regulator has cleared ChemChina’s US$43 billion takeover of Swiss pesticides and seeds group Syngenta, the companies said Monday, boosting chances that the largest foreign acquisition ever by a Chinese company will go through. The decision should remove significant uncertainty over whether the acquisition of the world’s largest pesticides maker

(Bayer.com)

Monsanto reported giving Bayer limited access to its books

Frankfurt | Reuters — U.S. seed company Monsanto has given German suitor Bayer limited access to its books after turning down a sweetened US$64 billion takeover offer last month, two sources familiar with the situation told Reuters. The parties have not yet signed a non-disclosure agreement, which would allow Bayer to conduct due diligence, but